Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery.

Proceedings of the National Academy of Sciences of the United States of America - 20 Mar 2012

Li Hairi, Zhou Hongyan, Wang Dong, Qiu Jinsong, Zhou Yu, Li Xiangqiang, Rosenfeld Michael G, Ding Sheng, Fu Xiang-Dong

Abstract excerpt

The advent of powerful genomics technologies has uncovered many fundamental aspects of biology, including the mechanisms of cancer; however, it has not been appropriately matched by the development of global approaches to discover new medicines against human diseases. Here we describe a unique high-throughput screening strategy by high-throughput sequencing, referred to as HTS(2), to meet this challenge. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgens
Share to Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemistry, Pharmaceutical

Share to Drug Design

Share to Drug Screening Assays, Antitumor

Share to Glycosides

Share to Proteasome Endopeptidase Complex

Share to RNA Interference

Source

Open in PubMed Open full text

Identifiers

PMID: 22396588
DOI: 10.1073/pnas.1200305109
PMCID: PMC3311343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery.PMID 22396588Read ↗

Integrative multi-omics and drug–response characterization of patient-derived prostate cancer primary cellsSemantic proximity Read ↗

Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate CancerSemantic proximity Read ↗

Innovating cancer drug discovery with refined phenotypic screens.Semantic proximity Read ↗

Mapping the Transcriptional Landscape of Drug Responses in Primary Human Cells Using High-Throughput DRUG-seqSemantic proximity Read ↗

Linking phenotypes and modes of action through high-content screen fingerprints.Semantic proximity Read ↗

Phenotype-Oriented Characterization of NSC828786 Identifies Convergent HPN-AMACR-Associated Transcriptomic Signatures in Prostate Adenocarcinoma and Broad-Spectrum Antiproliferative Activity.Semantic proximity Read ↗

Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids.Semantic proximity Read ↗

Linking chemicals, genes and morphological perturbations to diseases.Semantic proximity Read ↗

Genomic approaches for interrogating the biochemistry of medicinal plant species.Semantic proximity Read ↗

Gene-signature-derived IC50s/EC50s reflect the potency of causative upstream targets and downstream phenotypes.Semantic proximity Read ↗

From Traditional Biomarkers to Transcriptome Analysis in Drug DevelopmentSemantic proximity Read ↗

Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.